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Plasma Adiponectin Is Associated with Plasma Brain Natriuretic Peptide and Cardiac Function in Healthy Subjects
Takahiro OHARA 1) , Jiyoong KIM 1) , Masanori ASAKURA 1) , Hiroshi ASANUMA 1) , Satoshi NAKATANI 1) , Kazuhiko HASHIMURA 1) , Hideaki KANZAKI 1) , Tohru FUNAHASHI 2) Introduction Adiponectin is one of the circulating adipocytokines, and it plays a role in regulating insulin sensitivity, lipid metabolism, and systemic inflammation ( 1 ) . The plasma adiponectin level is decreased in persons with obesity, type 2 diabetes mellitus, dyslipidemia, hypertension, metabolic syndrome and ischemic heart disease ( 1 -5 ). We and others have previously reported that the severity of cardiac hypertrophy and subsequent heart failure is worsened in adiponectin knock-out mice subjected to pressure overload, suggesting that adiponectin may have a cardiovascular protective effect in patients with congestive heart failure (CHF) ( 6 -8 ) . Recent studies have indicated that the plasma adiponectin level is increased in patients with CHF, but the mechanism through which adiponectin production from adipose tissue is stimulated by CHF has not been elucidated ( 9 , 10 ) . The plasma brain natriuretic peptide (BNP) level has been reported to show a positive correlation with the plasma adiponectin level in patients with CHF or coronary heart disease ( 9 -12 ) . BNP secretion by the ventricular myocardium reflects the elevation of intracardiac pressure, and the circulating BNP level is related to the prognosis of CHF ( 13 , 14 ) . Even among apparently healthy subjects, relatively lower BNP levels predict a lower incidence of cardiovascular events, so BNP may reflect subtle hemodynamic changes in "healthy" persons ( 15 ) . However, the relationship between plasma levels of BNP and adiponectin in healthy subjects has not yet been examined, and there has been no investigation of the relationship between the plasma adiponectin level and cardiac function.
To elucidate the factors predicting the plasma adiponectin level and to investigate the relationship between adiponectin and cardiac function, we performed a cross-sectional study of 1,538 healthy subjects without CHF from Arita-cho, a rural area in Japan. We investigated the predictors of adiponectin, including BNP, and also assessed the relationship between the plasma adiponectin level and echocardiographic parameters of cardiac function.
Methods
The study was conducted in accordance with the Declaration of Helsinki, and was approved by the ethics committee of the National Cardiovascular Center and that of Arita-cho. Written informed consent was obtained from each subject before participation in this study in accordance with approved institutional protocols.
Study Population
We studied 1,538 persons from Arita-cho who had no clinical evidence of overt CHF. Laboratory tests, including plasma adiponectin and BNP levels, were performed in all subjects and 608 of them also underwent echocardiography.
Assays
The plasma concentration of adiponectin was measured using a specific immunoradiometric assay (2) . The plasma concentration of BNP was measured with a specific immunoradiometric assay for human BNP using a commercial kit (Shionoria; Shionogi Co., Ltd., Osaka, Japan) (14) . The insulin resistance index was determined by the homeostasis model assessment of insulin resistance (HOMA-R) method (16) .
Echocardiography
The left atrial diameter, the left ventricular end-diastolic and end-systolic dimensions, the left ventricular fractional shortening, and the left ventricular septal and posterior wall thickness were obtained by M-mode echocardiography. The left ventricular mean wall thickness was calculated by averaging the left ventricular septal and posterior wall thickness. All echocardiograms were read by physicians from the National Cardiovascular Center who were blinded to any clinical information about the subjects. Indexed values were calculated by dividing the results by the body surface area, which was calculated according to Mosteller (17) . The left ventricular mass was calculated using parameters measured by M-mode echocardiography (18) . Mitral inflow was assessed in the api- cal four-chamber view using pulsed-wave Doppler echocardiography, with the Doppler beam aligned parallel to the direction of the flow and the sample volume set at the leaflet tips. From the mitral inflow profile, the peak velocity of early diastolic transmitral flow, the peak velocity of late diastolic transmitral flow, and the early diastolic transmitral flow deceleration time were measured (19) .
Statistical Analysis
Numerical data are reported as the mean±SD or the median and interquartile range, as appropriate. Data on the levels of adiponectin, BNP, fasting insulin, triglycerides, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and γ-glutamyl transpeptidase (γ-GTP) were logarithmically transformed for linear regression analysis. Multivariate analysis was done to examine the correlations of log-transformed adiponectin levels with the variables that were associated with adiponectin (p< 0.10) according to simple regression analysis. The final model always included the following potentially confounding variables irrespective of the results of univariate analysis; age, sex, body mass index (BMI), ischemic heart disease, and atrial fibrillation. Fasting insulin levels and HOMA-R were not included in the final model because of missing data for a significant number of subjects.
Echocardiographic parameters were assessed for their relationship with adiponectin (log-transformed) by univariate analysis or analysis adjusted for age, gender, and BMI. Interaction effects of gender, age (65 years or older), ischemic heart disease, hypertension, diabetes mellitus, and hyperlipidemia on the relation between plasma adiponectin and BNP levels were examined with analysis of covariance. A probability (p) value < 0.05 was accepted as indicating statistical significance unless otherwise mentioned. A software package (SPSS 10.0.5J; SPSS, Chicago, USA) was used for statistical analysis.
Results
The profile of the subjects is shown in Table 1 . There was a significant positive correlation between their plasma BNP and adiponectin levels (Fig. 1) . This relationship was not influenced by covariates such as gender, age (65 years or older), ischemic heart disease, hypertension, diabetes mellitus, or hyperlipidemia. Table 2 shows the factors from among clinical, laboratory, and hemodynamic parameters that showed correlations with the plasma adiponectin levels. Univariate analysis revealed that male sex and diabetes mellitus were associated with lower adiponectin levels. The BMI, waist circumference, fasting blood glucose, fasting insulin, HOMA-R, triglycerides, hemoglobin, ALT, γ-GTP, uric acid, creatinine, and blood pressure were all negatively correlated with the plasma adiponectin level, whereas age, plasma BNP, and plasma highdensity lipoprotein (HDL)-cholesterol were positively correlated with adiponectin. Among these factors, it was found that male sex, waist circumference (but not BMI), and the plasma levels of triglycerides, AST, γ-GTP, and uric acid were negatively correlated with adiponectin by multivariate analysis, while there were positive correlations for age and the plasma levels of BNP, HDL-cholesterol, and creatinine. In the present cross-sectional study, sex was most strongly associated with the plasma adiponectin level, followed by age, according to the standardized regression coefficients (β). The plasma BNP level showed as strong an association with the plasma adiponectin level as did waist circumference, HDLcholesterol, and triglycerides.
Predictors of the Adiponectin Level

Echocardiographic Parameters
Since the plasma adiponectin level is elevated in patients with heart failure, we examined whether adiponectin was related to cardiac function. The baseline echocardiographic parameters are displayed in Table 3 .
According to univariate analysis (Table 4) , several echocardiographic parameters were related to the plasma adiponectin level, including the left atrial diameter index, left ventricular end-diastolic diameter index, the fractional shortening, the mean wall thickness, the left ventricular mass index, the late diastolic transmitral flow velocity, and the early/late diastolic transmitral flow velocity ratio. After adjustment for age, sex and BMI, however, only the left atrial diameter index and the left ventricular end-diastolic diameter index were positively correlated with the circulating adiponectin level.
Discussion
The present study demonstrated that the plasma adiponectin level was positively correlated with the plasma BNP level in healthy subjects along with known predictors such as the age, BMI, waist circumference, HDL-cholesterol, triglycerides, liver function parameters, uric acid, and renal function parameters. The plasma BNP level had the same influence on adiponectin as that of the waist circumference, HDL-cholesterol, and triglycerides. We also demonstrated that the plasma adi- BNP, brain natriuretic peptide; HOMA-R, homeostasis model assessment of insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure. *Log fasting insulin and HOMA-R were not included in the multivariate model, because insulin was not measured in a considerable number of subjects. 
Link between Plasma Adiponectin and BNP
The plasma adiponectin level is reported to be increased and to show a positive correlation with plasma BNP in CHF patients (9, 10) . It has been suggested that cardiac cachexia due to the progression of heart failure leads to an increase of plasma adiponectin levels (7). However, this study revealed that "healthy" subjects without cardiac cachexia also demonstrated a positive correlation between plasma adiponectin and BNP levels, suggesting that cardiac cachexia itself is unlikely to be the reason for the positive relationship between plasma adiponectin and BNP levels. In obese patients, BNP levels are lower, due to increased expression of the natriuretic clearance receptor in adipose tissue or some other unknown factor (20) . Because adiponectin levels are also lower in obese patients, one may argue that the relationship between the plasma adiponectin and BNP is confounded by obesity (2). Renal dysfunction is known to increase the levels of both adiponectin and BNP (21, 22) . However, the influence of obesity and renal dysfunction cannot explain the adiponectin-BNP relationship that was revealed by the present observational study, which found a tight relationship between plasma adiponectin and BNP independently of these potentially confounding factors.
The final possibility is that BNP directly increases adiponectin production. Indeed, we have preliminary data showing that BNP directly increases adiponectin mRNA expression in cultured 3T3-L1 adipocytes (data not shown). Wang et al. reported that low BNP was associated with metabolic risk factors in ambulatory individuals (23) , and that these risk factors could be mediated by adiponectin, which was consistent with a tight linkage between adiponectin and BNP levels. Higher levels of adiponectin could constitute a risk for CHF, and at the same time could be a negative risk for metabolic syndrome through their interaction with BNP; lower levels of BNP could constitute a negative risk for CHF and at the same a risk for metabolic syndrome through their interaction with adiponectin.
Adiponectin and Cardiac Function
Wang et al. reported that the extent of the increase in plasma BNP levels could predict cardiovascular mortality in subjects without CHF, indicating that subtle stress on the heart can be detected by monitoring BNP and this stress leads to cardiovascular events (15) .
We demonstrated that some conventional echocardiographic parameters (left atrial and left ventricular diameter indexes) showed a relationship with adiponectin similar to the relation of BNP to adiponectin. Previous studies of the relationship between adiponectin and BNP have also found no obvious cardiac dysfunction in their subjects, but they did not examine echocardiographic parameters (11, 12) .
Cardiac dimensions are not direct indexes of cardiac function. However, it is also the case that left ventricular dimensions are tightly related to cardiac function. As cardiac function is depressed, end-diastolic or systolic ventricular dimension increases, and vise versa. Even subjects with highnormal blood pressure suffer from some degree of left ventricular remodeling (24) . The left atrial dimension, a predictor of atrial fibrillation, reflects blood pressure levels and metabolic abnormalities in ambulatory settings (25) . Plasma adiponectin may increase to counteract these latent cardiac remodeling effects.
How does hemodynamics or structural change regulate adiponectin production? One possibility is that BNP directly causes an increase of adiponectin production, as mentioned above. Alternatively, there is a possibility that adiponectin is produced in the heart when it is placed under stress. It has been reported that adiponectin is synthesized and secreted by isolated murine and human cardiomyocytes (26) . However, the production of adiponectin by adipose tissue is greater than that by cardiac tissue (in part because the amount of adipose tissue is greater), suggesting that most of the circulating adiponectin is derived from adipose tissue.
Cardioprotective Role of BNP and Adiponectin
BNP is known to have a protective effect against cardiovascular injury via the cyclic GMP-G kinase pathway, and an increase of BNP is believed to improve the severity of heart failure (14, 27, 28) . BNP may exert a cardioprotective effect on subclinical heart disease (15). We and another group have recently reported that cardiac hypertrophy and subsequent heart failure are accelerated by aortic banding in adiponectin knock-out mice (6, 8) . Cardiac hypertrophy is believed to be a major risk factor for cardiovascular death, suggesting that adiponectin release is increased by stresses acting on the heart even in healthy subjects for prevention of cardiac injury like BNP (29) . Adiponectin may decrease the onset or the progression of CHF. Pioglitazone has been reported to increase adiponectin production via stimulation of peroxisome proliferator-activated receptor γ and it also reduces cardiac hypertrophy in mice with aortic banding (30) . Thus, adiponectin may be a target for prevention of overt CHF.
Clinical Implications
The positive correlation between plasma adiponectin and BNP levels in apparently healthy individuals in our study suggests that adiponectin can predict a worsening of prognosis or morbidity of heart failure even in healthy subjects. In addition, we need to consider whether latent heart failure and BNP levels should be taken into account when we examine subjects with higher adiponectin levels in clinical settings. Further prospective investigations are therefore warranted to determine whether high adiponectin levels are related to worse prognosis or future morbidity of heart failure even in healthy subjects.
Limitations
The present large-scale cross-sectional study showed a close relationship between adiponectin and BNP. However, the nature of a cross-sectional study means that we could not assess the prognostic impact of adiponectin in our healthy subjects. In CHF patients, high adiponectin levels are related to a worse prognosis, so longitudinal studies are needed to elucidate the impact of adiponectin on the prognosis in apparently healthy persons (9, 10) .
We used self-administered questionnaires to investigate the rates of risk factors and the current state of treatment. The percentages of subjects taking medication were 81%, 61%, and 68% for the patients with hypertension, diabetes mellitus, and hyperlipidemia, respectively. There were no significant differences in adiponectin and BNP values between those taking and those not taking medications. Thus medications do not seem to have influenced the results significantly.
Conclusions
The plasma adiponectin level increased along with an increase of the plasma BNP level in apparently healthy subjects, suggesting that plasma adiponectin reflects some aspects of cardiac function.
